Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
15. April 2024 16:09 ET
|
Imugene Limited
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
22. Februar 2024 10:10 ET
|
Imugene Limited
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight
23. März 2023 06:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight The bile duct cancer market is anticipated to surge in the...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
28. Mai 2021 08:51 ET
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
PCI Biotech first quarter 2021 interim results
07. Mai 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech to present at European Biotech Investor Days 2021
06. April 2021 06:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
26. Oktober 2020 07:48 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech's fourth quarter and preliminary 2019 results
26. Februar 2020 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...
Biliary Tumor Market to Gain Traction in the Coming Years; Advancements in NuCana’s Breakthrough Pipeline Drug Will Boost the Market, says Fortune Business Insights
19. Juni 2019 07:45 ET
|
Fortune Business Insights
Pune, June 19, 2019 (GLOBE NEWSWIRE) -- The global Biliary Tumor Market is likely to derive growth from increasing usage approvals in the forthcoming years. According to an upcoming report by...
Delcath Announces Enrollment of First Patient in ALIGN Trial
18. Oktober 2018 08:00 ET
|
Delcath Systems, Inc.
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...